SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000882104-20-000173
Filing Date
2020-10-07
Accepted
2020-10-07 16:01:48
Documents
15
Period of Report
2020-10-01
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pdli-20201001.htm   iXBRL 8-K 45981
2 EXHIBIT 99.1 a202010078-kex991.htm EX-99 438778
  Complete submission text file 0000882104-20-000173.txt   645599

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pdli-20201001.xsd EX-101.SCH 2405
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT pdli-20201001_cal.xml EX-101.CAL 698
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pdli-20201001_def.xml EX-101.DEF 1631
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pdli-20201001_lab.xml EX-101.LAB 23970
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pdli-20201001_pre.xml EX-101.PRE 12634
8 EXTRACTED XBRL INSTANCE DOCUMENT pdli-20201001_htm.xml XML 10480
Mailing Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451
Business Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451 775-832-8500
PDL BIOPHARMA, INC. (Filer) CIK: 0000882104 (see all company filings)

IRS No.: 943023969 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19756 | Film No.: 201229153
SIC: 2836 Biological Products, (No Diagnostic Substances)